

(COOH), 740 (C=C) cm^{-1} ; $^1\text{H NMR}$ (270 MHz) δ 0.94 (6 H, d, $J = 6.6$ Hz, $\text{CH}_3 \times 2$), 1.41, 1.66 (each 2 H, quint, $J = 7.5$ Hz, $\text{C}_{3,4}\text{-H}$), 2.06 (2 H, dt, $J = 7.3, 7.3, 5.9$ Hz, $\text{C}_5\text{-H}$), 2.36 (2 H, t, $J = 7.5$ Hz, $\text{C}_2\text{-H}$), 2.58 (1 H, m, $\text{C}_8\text{-H}$), 5.16-5.23 (2 H, m, $\text{CH}=\text{CH}$); (100 MHz) δ 11.50 (1 H, br s, COOH); EI-MS m/z (relative intensity) 170 (M^+ , 14), 152 ($\text{M}^+ - 18$, 13), 137 (19), 109 (13), 95 (28), 81 (22), 69 (100), 55 (77), 41 (85). Anal. Calcd for $\text{C}_{10}\text{H}_{18}\text{O}_2$: C, 70.54; H, 10.66. Found: C, 70.44; H, 10.66. This acid was esterified with CH_2N_2 , and the *E/Z* ratio was found to be 1:11 [*E* isomer (t_R 10.6 min); *Z*-isomer (t_R 10.3 min)] by GLC analysis.

Isomerization of the (*Z*)-Acid 3b. 2 M NaNO_2 (3.2 mL) and 6 M HNO_3 (2.15 mL) were added to the (*Z*)-acid 3b (7.7 g, 45.3 mmol) warmed at 70-75 °C under an atmosphere of N_2 .¹⁵ The mixture was then stirred vigorously for 0.5 h. The cooled reaction mixture was diluted with ether (50 mL), washed with water (50 mL) and saturated brine (30 mL \times 3), dried over anhydrous Na_2SO_4 , and evaporated. The oily residue was distilled under reduced pressure to give the (*E*)-acid 3a (5.94 g, 77%): bp 117-120 °C (2.8 Torr) [lit.⁹ bp 100-103 °C (3 Torr), lit.¹⁰ bp 130-132 °C (12 Torr), lit.¹² bp 120-122 °C (5-6 Torr)]. GLC analysis revealed that *E/Z* ratio of 3a was 8:1: IR (neat) 3300-2500 (COOH), 1710 (C=O), 970 (C=C) cm^{-1} ; $^1\text{H NMR}$ (270 MHz) δ 0.96 (6 H, d, $J = 6.6$ Hz, $\text{CH}_3 \times 2$), 1.41, 1.64 (each 2 H, quint, $J = 6.6$ Hz, $\text{C}_{3,4}\text{-H}$), 2.00 (2 H, q, $J = 6.6$ Hz, $\text{C}_5\text{-H}$), 2.35 (2 H, t, $J = 6.8$ Hz, $\text{C}_2\text{-H}$), 2.17-2.30 (1 H, m, $\text{C}_8\text{-H}$), 5.32-5.38 (2 H, m, $\text{CH}=\text{CH}$); (100 MHz) δ 11.50 (1 H, br s, COOH); FI-MS m/z (relative intensity) 171 (MH^+ , 19.9), 170 (M^+ , 100); EI-MS m/z (relative intensity) 170 (M^+ , 20), 152 (16), 137 (24), 109 (20), 95 (33), 81 (24), 69 (100), 55 (79), 41 (95). Anal. Calcd for $\text{C}_{10}\text{H}_{18}\text{O}_2$: C, 70.54; H, 10.66. Found: C, 70.69; H, 10.88.

Vanillylamine. A mixture of vanillin (15.2 g, 0.1 mol) and ammonium formate (20 g, 0.32 mol) was heated at 180 °C for 3 h²⁰ and, after cooling, evaporated until the odor of ammonia disappeared. To the residue was added concentrated HCl (12 mL). The mixture was refluxed for 1 h and then evaporated until the odor of HCl disappeared. The HCl salt was crystallized by adding EtOH (70 mL). Two recrystallizations from 95% EtOH yielded pure vanillylamine hydrochloride (8.99 g, 47.5%), mp 216-218 °C dec (lit.³ mp 219-222 °C dec, lit.¹⁰ mp 214 °C). IR and $^1\text{H NMR}$ data were identical with those reported in the literature.³ Anal. Calcd for $\text{C}_8\text{H}_{12}\text{NClO}_2$: C, 50.67; H, 6.38; N, 7.39; Cl, 18.70. Found: C, 50.44; H, 6.40; N, 7.47; Cl, 18.90.

To a vigorously stirred solution of vanillylamine hydrochloride (3.66 g, 19.31 mmol) in water (50 mL) was added 2 M NaOH solution (9.38 mL, 18.76 mmol). The resulting white solid of free vanillylamine was collected by suction filtration, washed with water, dried over P_2O_5 in a vacuum desiccator, and amounted to 2.54 g (89%), mp 135-136 °C (lit.⁹ mp 132 °C, lit.¹⁹ mp 131-133 °C), which was used in the following steps without further purification.

(*E*)-*N*-(4-Hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide (Capsaicin) (1a). The (*E*)-acid 3a (334 mg, 1.96 mmol) and thionyl chloride (720 mg, 5.88 mmol) were stirred at room temperature for 8 h and then heated at 100 °C for 0.5 h. The excess thionyl chloride was removed under reduced pressure. The resulting acid chloride 4a [bp 100-102 °C (12 Torr)]²⁴ was dissolved in dry ether (10 mL) and added to a stirred suspension of dry vanillylamine (600 mg, 3.92 mmol) in dry ether (25 mL) under an atmosphere of N_2 . The mixture was kept at room temperature for 2 h and then gently refluxed for 2 h. After cooling, the precipitate was removed by suction filtration, and the filtrate was evaporated. The residue was purified by column chromatography on silica gel (Fuji-gel BW-200, 15 g, elution with 2:1 hexane-ethyl acetate). The oily product (542 mg, *E/Z* = 8:1,²⁵ 91%) was treated with 2:1 hexane-ether to give a crystalline solid (473 mg, *E/Z* = 12:1,²⁵ 79%), mp 60-63 °C. Two recrystallizations from the same solvents gave capsaicin (318 mg, 53%), mp 64-65 °C (lit.^{3,8,12} mp 64-65 °C, lit.⁹ mp 63.8 °C, lit.¹⁰ mp 65 °C) as a white solid. IR, $^1\text{H NMR}$, and mass spectral data were essentially identical with those reported in the literatures.^{3,9} Anal. Calcd

for $\text{C}_{18}\text{H}_{27}\text{NO}_3$: C, 70.79; H, 8.91; N, 4.59. Found: C, 70.69; H, 9.02; N, 4.49.

(*Z*)-*N*-(4-Hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide (*cis*-Capsaicin) (1b). The (*Z*)-acid 3b (464 mg, 2.72 mmol) was treated with thionyl chloride (1.0 g, 8.17 mmol) in the same manner as noted above. The obtained acid chloride 4b [bp 99-102 °C (13 Torr)]²⁴ in dry ether (10 mL) was added to a suspension of dry vanillylamine (835 mg, 5.45 mmol) in dry ether (30 mL) under an atmosphere of N_2 . The workup in the same manner as noted above gave the crude oily amide 1b (745 mg, *E/Z* = 1:11,²⁵ 90%), which on crystallization from 2:1 hexane-ether afforded a crystalline solid (674 mg, 81%, *E/Z* = 1:13).²⁵ Two recrystallizations from the same solvents afforded *cis*-capsaicin (1b) (548 mg, 66%), mp 68.5-69.5 °C (lit.²³ mp 70 °C), as a white solid. IR, $^1\text{H NMR}$, and mass spectral data were essentially identical with those reported by Gannett et al.³ Anal. Calcd for $\text{C}_{18}\text{H}_{27}\text{NO}_3$: C, 70.79; H, 8.91; N, 4.59. Found: C, 70.78; H, 9.08; N, 4.61.

Nitrobenzophenone Oxime Based Resins for the Solid-Phase Synthesis of Protected Peptide Segments¹

Mark A. Findeis* and Emil Thomas Kaiser²

Laboratory of Bioorganic Chemistry and Biochemistry,
The Rockefeller University, 1230 York Avenue,
New York, New York 10021

Received January 31, 1989

This laboratory has reported the development of an oxime resin that allows the rapid synthesis and isolation of protected peptides.^{3,4} This oxime support has been used successfully in the synthesis of an apolipoprotein model peptide⁵ and a synthetic hemeprotein⁶ and is now being applied in the syntheses of several small proteins.^{7,8} During our efforts to synthesize peptides corresponding to partial and full sequences of our target proteins we have encountered difficulties in the use of our polystyrene-based oxime resin both in the synthesis of specific sequences of certain short peptides (<10 residues) and in the recoupling of smaller protected peptide segments on the oxime resin to assemble large peptides. Difficulties in the latter instance have necessitated the use of solution-phase couplings to couple larger protected peptides of about >15 residues. Nevertheless, we would still like to have a solid support as an effective option for use in the coupling of protected peptide segments. This paper describes our initial effort to explore alternative oxime solid-phase supports for the synthesis and assembly of protected peptides through the synthesis of a nitrobenzophenone oxime derivative and its attachment to a polyamide resin. We also report an improved procedure for the synthesis of our previously reported polystyrene-based oxime resin 1.^{3,4}

Results and Discussion

Because the 4-nitrobenzophenone oxime (NBO) moiety has proved reliable in previous synthetic work, we decided to synthesize a molecule that would contain the NBO functionality and, in addition, a linker arm through which the oxime could be attached to a solid support. While the standard oxime resin is obtained by direct modification of polystyrene beads (Scheme I), this new approach offers

(23) Rangoonwala, R.; Seitz, G. *Deut. Apoth.-Ztg.* 1970, 110, 1946.

(24) The boiling points of the acid chlorides 4a,b were determined by distillation (85-90% yields) in other runs.

(25) The *E/Z* ratio was determined on intensities of isopropyl signals by $^1\text{H NMR}$ analysis.

* Author to whom correspondence should be addressed at: Arteriosclerosis Center, Department of Medicine, Deaconess Hospital, 110 Francis Street, Suite 7F, Boston, MA 02215.